Supportive Care in Cancer

, Volume 15, Issue 1, pp 63–71

The emerging role of cannabinoid neuromodulators in symptom management

  • Mellar Davis
  • Vincent Maida
  • Paul Daeninck
  • Joseph Pergolizzi
Original Article

DOI: 10.1007/s00520-006-0180-0

Cite this article as:
Davis, M., Maida, V., Daeninck, P. et al. Support Care Cancer (2007) 15: 63. doi:10.1007/s00520-006-0180-0



The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy.


The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain.


The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.


Cannabinoids Chemotherapy-induced nausea and vomiting CB1 and CB2 receptors Pain 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Mellar Davis
    • 1
  • Vincent Maida
    • 2
    • 3
  • Paul Daeninck
    • 4
    • 5
    • 6
  • Joseph Pergolizzi
    • 7
    • 8
    • 9
  1. 1.The Harry R. Horvitz Center for Palliative MedicineCleveland ClinicClevelandUSA
  2. 2.William Osler Health CenterTorontoCanada
  3. 3.University of TorontoTorontoCanada
  4. 4.Departments of Internal and Family MedicineUniversity of ManitobaWinnipegCanada
  5. 5.CancerCare ManitobaWinnipegCanada
  6. 6.Winnipeg Regional Palliative Care ProgramWinnipegCanada
  7. 7.Johns Hopkins University School of MedicineBaltimoreUSA
  8. 8.Coalition of Pain Education (COPE)National Institute of PainNew YorkUSA
  9. 9.Naples Anesthesia and Pain AssociatesNaplesUSA

Personalised recommendations